Reclast (Zoledronic Acid) Pediatric (Under 12) Safety: What Clinicians and Parents Need to Know

The direct answer

Zoledronic acid has no FDA-approved pediatric indication under age 12; every use in this age group is off-label, extrapolated from adult osteoporosis and oncology data plus a limited set of pediatric trials and case series concentrated in osteogenesis imperfecta. The drug's known risks, an acute post-infusion inflammatory reaction, hypocalcemia, and renal excretion-dependent toxicity, are the same risks seen in adults, but children carry them with a body that is still growing and a kidney whose filtration capacity is still maturing. Whether zoledronic acid is appropriate for a specific child under 12 is a specialist decision that depends on the underlying bone disease, baseline renal and calcium status, and access to structured pre- and post-infusion monitoring, not a question with a single population-wide answer.

What zoledronic acid is and why it is used in young children

Zoledronic acid is a nitrogen-containing bisphosphonate. It binds hydroxyapatite in bone and inhibits osteoclast-mediated bone resorption by blocking the mevalonate pathway enzyme farnesyl pyrophosphate synthase. Reclast is the 5 mg once-yearly intravenous formulation FDA-approved for osteoporosis and Paget's disease in adults. Zometa is a separate 4 mg formulation approved for oncology indications such as bone metastases and hypercalcemia of malignancy. Neither carries FDA approval for use in children.

Its once-yearly IV schedule is the practical reason clinicians reach for it in children who cannot reliably take oral bisphosphonates or whose families face a heavy travel burden for more frequent infusions. Off-label pediatric use concentrates in a handful of orphan-disease scenarios: osteogenesis imperfecta (a genetic collagen disorder causing recurrent fractures and skeletal deformity), glucocorticoid-induced secondary osteoporosis, and immobilization-related bone loss in non-ambulatory children, most often those with cerebral palsy.

Pamidronate, an older intravenous bisphosphonate given in quarterly multi-day infusion cycles, has a longer pediatric track record and remains first-line at many centers, particularly for infants and very young children. Zoledronic acid is increasingly considered as an alternative because of its lower visit burden, and small comparative trials in osteogenesis imperfecta have reported broadly similar bone density gains between the two drugs over about a year of treatment, with more first-dose acute-phase reactions in the zoledronic acid group. The exact trial identifiers behind this comparison require verification against the primary literature before being cited with specific numbers; the qualitative pattern (comparable short-term densitometric response, different reaction profile, very different visit burden) is the part of this comparison that is reasonably well established across multiple published case series.

What FDA labeling actually says

The FDA has not approved zoledronic acid, in either the Reclast or Zometa formulation, for any pediatric indication. Prescribing information states that safety and efficacy in pediatric patients have not been established for the labeled adult indications. Because there is no labeled pediatric dose, everything below describing a pediatric dosing range reflects published practice patterns and expert consensus, not an FDA-sanctioned regimen. A prescribing clinician using zoledronic acid in a child under 12 is practicing off-label medicine and should document the clinical rationale and obtain informed consent that states plainly that the drug is not FDA-approved for this use in this age group. Readers relying on the exact current label language (dose caps, renal cutoffs, contraindications) should confirm it directly against the current FDA label rather than a secondhand summary, since labels are revised periodically.

Main safety risks in children under 12

Acute-phase reaction

Children typically experience an acute-phase reaction within one to three days of their first zoledronic acid infusion, characterized by fever, myalgia, arthralgia, headache, and fatigue. This response results from transient cytokine release (including tumor necrosis factor-alpha and interleukin-6) following gamma-delta T-cell activation. Published pediatric series indicate the reaction occurs frequently after initial treatment but becomes substantially less common with repeated annual infusions. Reported rates differ across studies and should be verified in the original literature rather than cited as a universal figure. Anticipatory antipyretic medication given before and after infusion represents standard care for minimizing symptom intensity, although some children may still experience the reaction despite this preventive approach.

Hypocalcemia

Zoledronic acid acutely suppresses osteoclast activity, which reduces the calcium normally released from bone. In a child with unrecognized vitamin D insufficiency or low calcium intake, this can produce symptomatic hypocalcemia in the first one to two days after infusion, presenting as perioral tingling, cramping, or, in severe cases, tetany or seizures. The standard prevention approach is to correct vitamin D status and ensure age-appropriate calcium intake before the infusion is scheduled, and to continue calcium supplementation for a period afterward in children whose bone remodeling suppression is expected to be greatest (notably those with osteogenesis imperfecta or recent glucocorticoid exposure).

Renal toxicity

Zoledronic acid is cleared almost entirely by the kidney, unchanged, without hepatic metabolism. Infusing it too quickly or in a dehydrated patient can cause acute kidney injury, which is why the adult label restricts use below a defined creatinine clearance threshold and specifies a minimum infusion time. Children have smaller body surface area and, at younger ages, immature glomerular filtration, which can amplify drug exposure per unit of body weight relative to an adult given a weight-adjusted dose. Most pediatric bone programs use an estimated GFR formula (such as the Schwartz equation) before each annual infusion, avoid the drug in children with significant chronic kidney disease, ensure adequate hydration before infusion, and extend the infusion time beyond the adult minimum as an added safety margin. The exact eGFR cutoff used in adults has not been separately validated as a pediatric threshold; centers extrapolate it as a cautious floor rather than a pediatric-specific standard.

Effects on growing bone

This is where pediatric use diverges most from adult use as a matter of biological plausibility rather than settled fact. Bisphosphonates incorporate into bone matrix and suppress osteoclast activity for a long period after dosing stops. In a growing skeleton, normal longitudinal bone growth depends on coordinated resorption at the growth plate. Dense transverse metaphyseal bands ("zebra lines") are a recognized radiographic finding after bisphosphonate therapy in children and reflect this suppressed remodeling at the growth front. Published osteogenesis imperfecta cohorts have generally not shown clinically significant growth arrest at the doses used for fragility fracture prevention, and reported height velocity during treatment has been near normal in several series. What is not established is the effect of dosing that continues for more than three to five years through the entirety of a child's growth period; long-term pediatric data at that duration are limited, and this is a genuine open question rather than a resolved reassurance.

Osteonecrosis of the jaw and atypical femoral fracture

Both are recognized bisphosphonate-associated adverse effects in adults, particularly at the high cumulative doses used in oncology. In pediatric fragility-fracture dosing (much lower cumulative exposure, once-yearly rather than monthly infusion), osteonecrosis of the jaw has been reported only as isolated cases in the pediatric literature, and dental clearance before starting therapy remains a reasonable precaution even though absolute risk appears low. Atypical femoral fracture has an established, if still debated, incidence in adults on long-term bisphosphonate therapy; no reliable pediatric-specific incidence estimate exists, and distinguishing an atypical fracture from an osteogenesis-imperfecta-related fracture on imaging is genuinely difficult in this population. Children on multi-year zoledronic acid therapy should be asked about new thigh or groin pain at each visit.

How comparative bisphosphonate evidence outside pediatrics does and does not apply

Larger, more recent systematic reviews comparing bisphosphonates with denosumab exist, but they were conducted in adult oncology populations, for example in breast cancer bone metastases and multiple myeloma, not in children or in fragility-fracture bone disease (systematic review of denosumab versus bisphosphonates in breast cancer bone metastases; systematic review of bisphosphonates and denosumab in multiple myeloma). These reviews are useful for understanding the general safety and comparative profile of the bisphosphonate drug class in adults, including renal and jaw-related adverse event patterns, but their populations, doses, and treatment durations do not transfer to a child receiving low-dose annual zoledronic acid for a skeletal fragility disorder. They should not be cited as pediatric evidence.

Dosing patterns used in practice (not an FDA-labeled dose)

Because there is no FDA-labeled pediatric dose, published practice patterns describe weight-based dosing generally in the range of 0.025 to 0.05 mg/kg IV, given once yearly, with a ceiling near 4 mg per infusion. Some centers start bisphosphonate-naive children at the lower end of that range for the first infusion specifically to blunt the acute-phase reaction, then move to the higher end for subsequent annual doses. Infusion time in pediatric protocols is commonly extended well beyond the adult minimum. None of this constitutes dosing instruction for an individual child; actual dose, interval, and infusion duration must be determined by the treating pediatric specialist based on the child's diagnosis, weight, renal function, and institutional protocol.

What labs are typically checked before each infusion

A pre-dose safety screen in a child under 12 typically includes:

• Serum creatinine with an estimated GFR calculation
• Corrected serum calcium (accounting for albumin)
• Serum phosphorus
• 25-OH vitamin D
• Serum magnesium, particularly in children on proton pump inhibitors or with malabsorption

Low vitamin D is generally corrected with supplementation for several weeks before rescheduling the infusion, and uncorrected hypocalcemia is treated as a reason not to proceed. Bone density is typically tracked with DXA using pediatric Z-scores, not adult T-scores, since T-scores are not appropriate before skeletal maturity.

Guideline landscape

Pediatric bone specialty organizations and bone-density measurement societies have published general practice guidance stating that bisphosphonate therapy can be appropriate for children with osteogenesis imperfecta and a history of vertebral compression fractures or multiple long-bone fractures, and that treatment decisions should rest on fracture history together with DXA findings rather than a low DXA Z-score alone. None of the major guideline bodies has published a standalone recommendation naming zoledronic acid specifically, or a preferred dose, for children under 12. Readers who need the exact current wording of a specific society's position should verify it against that society's current published statement rather than a secondhand summary, since pediatric bone guidance has been revised over time.

Special populations

Infants and toddlers under 2. Data specific to zoledronic acid in this age group are limited to individual case reports. Pamidronate has the more established track record in infants with severe osteogenesis imperfecta, and the relationship between immature renal function and zoledronic acid clearance in infants has not been formally characterized. This is an area where extrapolation from older-child data is weakest.

Children with cerebral palsy and immobilization osteoporosis. Controlled pediatric trial data in this population are concentrated on pamidronate rather than zoledronic acid. Zoledronic acid use in non-ambulatory children with low bone density is generally extrapolated from osteogenesis imperfecta dosing rather than supported by its own controlled trials in cerebral palsy.

Children on chronic glucocorticoids. Prolonged glucocorticoid exposure causes bone loss through several mechanisms, and adult guidelines list bisphosphonates as first-line therapy for high-risk adults on glucocorticoids. Pediatric-specific dosing guidance for glucocorticoid-induced osteoporosis is acknowledged as limited, and use of zoledronic acid in this setting is typically extrapolated from osteogenesis imperfecta protocols rather than from dedicated trials in glucocorticoid-treated children.

Stopping treatment and what happens afterward

Zoledronic acid has a long skeletal half-life, commonly described as persisting in cortical bone well beyond a decade, so its pharmacologic effect continues long after the last infusion. In adults, planned drug holidays after several years of bisphosphonate therapy are standard practice. In children, the analogous idea, pausing therapy once fracture rate, DXA trend, and growth velocity are all stable, is used at some centers but has not been formally studied as a protocol. Retrospective series in osteogenesis imperfecta populations have reported that bone density gains persist for a period of months to a couple of years after stopping annual infusions, without a clear rebound in fracture rate during that window, though exact figures from any single study should be confirmed against the original paper before being restated as a precise number.

Evidence boundary: what is established, what is plausible, what is not established

Established. Zoledronic acid is not FDA-approved for children under 12. It is cleared renally and can cause acute kidney injury if infused rapidly or in a dehydrated child. It commonly causes an acute-phase reaction after the first infusion. It can precipitate hypocalcemia in a child with uncorrected vitamin D deficiency. Metaphyseal banding on X-ray is a recognized finding after pediatric bisphosphonate therapy.

Plausible but not firmly established. That once-yearly zoledronic acid produces bone density gains in osteogenesis imperfecta comparable to quarterly pamidronate with fewer hospital visits. That current low-dose pediatric regimens carry a low but nonzero risk of osteonecrosis of the jaw and atypical femoral fracture, at a rate too low to have been precisely quantified in this population.

Not established. The long-term (beyond roughly five years) effect of continuous annual zoledronic acid dosing on final adult height and growth-plate integrity in children who start treatment before age 12. A pediatric-specific renal cutoff or drug clearance profile distinct from the adult data it is extrapolated from. Safety and dosing in infants under 2 years, where evidence is limited to isolated case reports.

A site-readiness and risk-screening framework before a first pediatric infusion

This framework is meant to organize a conversation between a prescribing pediatric specialist, the infusion center, and the family before a child under 12 receives a first dose of zoledronic acid off-label. It does not replace individualized clinical judgment or institutional protocol.

Step 1: Confirm the off-label basis is documented.

• Diagnosis supporting bisphosphonate therapy (for example, osteogenesis imperfecta with recurrent fracture, or glucocorticoid-induced osteoporosis with a fragility fracture) is recorded, not just a low DXA Z-score alone.
• Informed consent explicitly states the drug is not FDA-approved for this age group and indication.

Step 2: Screen for a reason not to proceed (stop and reassess if any are present).

• Estimated GFR below the threshold used in the treating center's protocol.
• Corrected serum calcium below the lower limit of normal.
• Active dental infection or planned invasive dental work in the near term.
• Dehydration or acute illness on the day of infusion.

Step 3: Correct modifiable risk before scheduling.

• 25-OH vitamin D below a deficient threshold: supplement and recheck before scheduling rather than infusing on the same visit.
• Inadequate dietary calcium intake for age: address with the family in advance.

Step 4: Plan the infusion itself.

• Hydration before infusion.
• Infusion time extended beyond the adult minimum, per center protocol.
• Antipyretic premedication planned, with a plan for breakthrough fever or myalgia at home.

Step 5: Plan monitoring after the infusion.

• Serum calcium recheck in the first one to two days for children at elevated hypocalcemia risk (recent vitamin D deficiency, osteogenesis imperfecta, recent glucocorticoid exposure).
• Serum creatinine recheck for children with borderline baseline renal function.
• A named clinician responsible for reviewing these results, not left solely to the infusion center.

Step 6: Plan the annual reassessment.

• DXA Z-score trend at appropriate intervals.
• Growth velocity tracked at each visit.
• After roughly three years of continuous annual dosing, consider periodic femur imaging and ask about new thigh or groin pain.
• Reassess whether continued therapy is still justified based on fracture rate, DXA trend, and growth, rather than continuing indefinitely by default.

When urgent care is appropriate

A child who develops facial or hand tingling, muscle cramping, or any suggestion of tetany or seizure activity after an infusion needs urgent medical evaluation for possible hypocalcemia. A child with high fever that does not respond to antipyretics, signs of dehydration, or reduced urine output after an infusion needs prompt evaluation for renal injury or an atypical infectious process rather than being assumed to have a routine acute-phase reaction. New jaw pain, exposed bone in the mouth, or new thigh/groin pain in a child on long-term therapy warrants specialist follow-up rather than reassurance by phone.